Mismatch Repair Loss Renders ER+(plus)/HER2- Breast Cancer Susceptible to HER2/3 Inhibition
Abstract
The objective of this proposed study is to investigate a role for HER2/3 activation in MutLdefective ER+ breast cancer progression and resistance to endocrine therapy. By targeting HER2/3 signaling and key nodes of adaptive kinome response, we aim to significantly improve patient disease-specific survival.
Document Details
- Document Type
- Technical Report
- Publication Date
- Nov 01, 2021
- Accession Number
- AD1191305
Entities
People
- Meghashyam Kavuri
Organizations
- Baylor College of Medicine